ADIA Nutrition Inc. Ignites 2025 with February Breakthroughs, Riding Adia Med's Profitable January Triumph
ADIA Nutrition Inc. (OTC Pink: ADIA) reports significant developments in February 2025, following a profitable January at its Winter Park Clinic. Key February milestones include: entering the $15.1B global stem cell market on February 3, appointing a PCAOB-registered accounting firm for OTCQB uplisting on February 5, and pledging to retire 25M undocumented shares (15% reduction) on February 11.
The company launched Adia Labs on February 20, introducing Adia Vita stem cell product. On February 24, they announced nationwide expansion through Medical Spa partnerships. By February 26, OTC Markets removed ADIA's shell risk designation, advancing their OTCQB uplisting goals.
The company's medical division, Adia Med, offers FDA-compliant stem cell treatments using umbilical cord products, targeting inflammation, autoimmune disorders, and orthopedic issues. Their Winter Park Clinic exceeded financial expectations in January 2025, covering all opening expenses with surplus revenue.
ADIA Nutrition Inc. (OTC Pink: ADIA) riporta sviluppi significativi a febbraio 2025, dopo un gennaio proficuo presso la sua Clinica di Winter Park. I principali traguardi di febbraio includono: l'ingresso nel mercato globale delle cellule staminali da 15,1 miliardi di dollari il 3 febbraio, la nomina di una società di contabilità registrata presso il PCAOB per l'up-listing OTCQB il 5 febbraio e l'impegno a ritirare 25 milioni di azioni non documentate (riduzione del 15%) l'11 febbraio.
La società ha lanciato Adia Labs il 20 febbraio, introducendo il prodotto Adia Vita a base di cellule staminali. Il 24 febbraio, hanno annunciato un'espansione nazionale attraverso partnership con Medical Spa. Entro il 26 febbraio, i mercati OTC hanno rimosso la designazione di rischio shell per ADIA, avanzando i loro obiettivi di up-listing OTCQB.
La divisione medica dell'azienda, Adia Med, offre trattamenti con cellule staminali conformi alla FDA utilizzando prodotti da cordone ombelicale, mirando a infiammazioni, disturbi autoimmuni e problemi ortopedici. La loro Clinica di Winter Park ha superato le aspettative finanziarie a gennaio 2025, coprendo tutte le spese di apertura con entrate in surplus.
ADIA Nutrition Inc. (OTC Pink: ADIA) informa sobre desarrollos significativos en febrero de 2025, tras un enero rentable en su Clínica de Winter Park. Los hitos clave de febrero incluyen: la entrada en el mercado global de células madre de 15.1 mil millones de dólares el 3 de febrero, la designación de una firma contable registrada en PCAOB para el uplisting OTCQB el 5 de febrero, y el compromiso de retirar 25 millones de acciones no documentadas (reducción del 15%) el 11 de febrero.
La empresa lanzó Adia Labs el 20 de febrero, presentando el producto de células madre Adia Vita. El 24 de febrero, anunciaron una expansión a nivel nacional a través de asociaciones con Medical Spa. Para el 26 de febrero, los Mercados OTC eliminaron la designación de riesgo shell de ADIA, avanzando en sus objetivos de uplisting OTCQB.
La división médica de la compañía, Adia Med, ofrece tratamientos con células madre conformes a la FDA utilizando productos de cordón umbilical, enfocados en la inflamación, trastornos autoinmunes y problemas ortopédicos. Su Clínica de Winter Park superó las expectativas financieras en enero de 2025, cubriendo todos los gastos de apertura con ingresos excedentes.
ADIA Nutrition Inc. (OTC Pink: ADIA)는 2025년 2월에 중요한 발전을 보고하며, 이는 Winter Park 클리닉에서의 수익성 있는 1월 이후의 일입니다. 2월의 주요 이정표로는 2월 3일 151억 달러 규모의 글로벌 줄기세포 시장에 진입, 2월 5일 OTCQB 상장을 위한 PCAOB 등록 회계법인 임명, 2월 11일 2500만 주의 비문서화된 주식(15% 감소) 매입 약속이 포함됩니다.
회사는 2월 20일 Adia Labs를 출시하며 Adia Vita 줄기세포 제품을 소개했습니다. 2월 24일에는 Medical Spa 파트너십을 통해 전국적으로 확장한다고 발표했습니다. 2월 26일까지 OTC 시장은 ADIA의 쉘 리스크 지정을 제거하여 OTCQB 상장 목표를 진전시켰습니다.
회사의 의료 부문인 Adia Med는 제대 혈액 제품을 사용하여 FDA 규정을 준수하는 줄기세포 치료를 제공하며, 염증, 자가면역 질환 및 정형외과적 문제를 대상으로 하고 있습니다. Winter Park 클리닉은 2025년 1월에 재정적 기대치를 초과하여 모든 개장 비용을 초과 수익으로 충당했습니다.
ADIA Nutrition Inc. (OTC Pink: ADIA) rapporte des développements significatifs en février 2025, suite à un mois de janvier rentable dans sa Clinique de Winter Park. Les principales étapes de février incluent : l'entrée sur le marché mondial des cellules souches de 15,1 milliards de dollars le 3 février, la nomination d'un cabinet comptable enregistré auprès du PCAOB pour l'up-listing OTCQB le 5 février, et l'engagement de retirer 25 millions d'actions non documentées (réduction de 15 %) le 11 février.
L'entreprise a lancé Adia Labs le 20 février, introduisant le produit de cellules souches Adia Vita. Le 24 février, ils ont annoncé une expansion nationale par le biais de partenariats avec des Medical Spas. D'ici le 26 février, les marchés OTC ont supprimé la désignation de risque shell d'ADIA, faisant progresser leurs objectifs d'up-listing OTCQB.
La division médicale de l'entreprise, Adia Med, propose des traitements par cellules souches conformes à la FDA utilisant des produits de cordon ombilical, ciblant l'inflammation, les troubles auto-immuns et les problèmes orthopédiques. Leur Clinique de Winter Park a dépassé les attentes financières en janvier 2025, couvrant toutes les dépenses d'ouverture avec des revenus excédentaires.
ADIA Nutrition Inc. (OTC Pink: ADIA) berichtet über bedeutende Entwicklungen im Februar 2025, nach einem profitablen Januar in seiner Winter Park Klinik. Zu den wichtigsten Meilensteinen im Februar gehören: der Eintritt in den globalen Markt für Stammzellen im Wert von 15,1 Milliarden Dollar am 3. Februar, die Ernennung einer beim PCAOB registrierten Wirtschaftsprüfungsgesellschaft für das OTCQB-Uplisting am 5. Februar und das Versprechen, 25 Millionen undokumentierte Aktien (15% Reduktion) am 11. Februar zurückzukaufen.
Das Unternehmen hat am 20. Februar Adia Labs gegründet und das Produkt Adia Vita für Stammzellen vorgestellt. Am 24. Februar kündigten sie eine landesweite Expansion durch Partnerschaften mit Medical Spas an. Bis zum 26. Februar entfernten die OTC-Märkte die Shell-Risiko-Bezeichnung von ADIA und förderten damit ihre OTCQB-Uplisting-Ziele.
Die medizinische Abteilung des Unternehmens, Adia Med, bietet FDA-konforme Stammzellbehandlungen unter Verwendung von Nabelschnurprodukten an, die auf Entzündungen, Autoimmunerkrankungen und orthopädische Probleme abzielen. Ihre Winter Park Klinik übertraf die finanziellen Erwartungen im Januar 2025 und deckte alle Eröffnungskosten mit Überschuss Einnahmen.
- Successful removal of shell risk designation, advancing OTCQB uplisting potential
- Winter Park Clinic profitable in first month of operations
- 15% share reduction through retirement of 25M undocumented shares
- Entry into $15.1B global stem cell market
- Nationwide expansion plan through Medical Spa partnerships
- Currently trading on OTC Pink, indicating lower tier market status
- Undocumented share issuance concerns in company history
Winter Park, Florida--(Newsfile Corp. - February 28, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a pioneer in healthcare innovation and regenerative medicine, concludes an extraordinary February with groundbreaking advancements in stem cell therapies, strategic partnerships, and a pivotal corporate milestone. These achievements, layered atop January's financial triumph at the Adia Med Winter Park Clinic, underscore ADIA Nutrition's unstoppable momentum toward revolutionizing healthcare, enhancing investor visibility, and delivering cutting-edge solutions nationwide.
February's transformative journey began on February 3, when Adia Med, the medical division of ADIA Nutrition, officially entered the
The month gained further traction mid-February. On February 11, ADIA Nutrition tackled historical share issuance concerns, pledging to retire over 25 million undocumented shares-cutting outstanding shares by approximately 15 percent-and reinforcing its commitment to shareholder integrity. On February 13, Adia Med advanced its registration with Florida's Agency for Health Care Administration (AHCA), aiming to secure private insurance coverage for therapies like Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and stem cell injectables, enhancing affordability. On February 18, a partnership with a premier FDA-approved laboratory ensured a steady supply of top-tier umbilical cord stem cell and exosome products, featuring 100 million viable cells and 3 trillion exosomes per dose, cementing Adia Med's leadership in regenerative medicine quality.
February's pinnacle arrived with three standout milestones that underscored ADIA Nutrition's rapid progress in regenerative medicine and corporate growth. These achievements highlighted the company's innovation, scalability, and commitment to enhancing investor confidence, marking a transformative close to the month.
February's Standout Milestones:
February 20: ADIA Nutrition launched Adia Labs LLC, unveiling Adia Vita-a branded stem cell product containing 100 million viable cells and 3 trillion exosomes per dose for clinical research and therapeutic use, targeting a market of over 1 million doctors and clinics.
February 24: Adia Med announced a nationwide expansion plan, partnering with elite Medical Spas to create satellite locations in health-conscious regions, offering a scalable, low-risk model to boost revenue and service reach.
February 26: ADIA Nutrition achieved a critical corporate victory as OTC Markets removed its shell risk designation, a key requirement for OTCQB uplisting, expedited through close collaboration with OTC Markets, highlighting the company's operational integrity and accelerating its path to greater liquidity and investor trust.
These February triumphs build on January's success, when the Adia Med Winter Park Clinic exceeded financial expectations in its first operational month, covering all opening expenses with surplus revenue. Treating conditions like Multiple Sclerosis (MS), hip issues, torn tendons, and joint pain with umbilical cord stem cells (UCB-SC), the clinic demonstrated the wide-reaching impact of its regenerative therapies. "January's financial strength gave us a solid base, and February's leaps-including the shell risk removal and Adia Labs' progress-propel us forward," said Larry Powalisz, CEO of ADIA Nutrition. "We're thrilled to thank OTC Markets for their swift support in clearing this hurdle, allowing me to share exciting updates with our investors that I couldn't before. This is just the start."
The OTCQB uplisting process, now in clear sight with the shell risk designation lifted, will elevate ADIA Nutrition's visibility to a broader investor audience. The Med Spa partnerships will efficiently scale operations, while the lab collaboration ensures product excellence. The share retirement effort further solidifies corporate governance, amplifying investor confidence, as ADIA Nutrition strengthens its position as a leader in regenerative medicine innovation.
Looking forward, ADIA Nutrition plans to replicate the Winter Park Clinic model in new markets, expand satellite locations, and complete its OTCQB uplisting with Nasdaq aspirations on the horizon. These efforts promise enhanced shareholder value and cutting-edge care for diverse communities. "From January's financial win to February's strategic breakthroughs, we're redefining healthcare possibilities," Powalisz added. "We're committed to innovation, accessibility, and sustainable growth for our stakeholders."
For questions, inquiries, or further information, contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
ADIA Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, it operates two key divisions: a supplement division offering premium, organic supplements, and a medical division establishing clinics specializing in leading-edge stem cell therapies, including Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these efforts, ADIA Nutrition empowers individuals to live their best lives by addressing nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adia-med.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor:
This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current plans and expectations and are subject to uncertainties and risks that could significantly affect the company's plans, expectations, and future results. A detailed list of risks and factors is available in reports filed with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to update or revise these statements due to new information, future events, or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/242492
FAQ
What major milestones did ADIA Nutrition (ADIA) achieve in February 2025?
How many undocumented shares will ADIA retire in their February 2025 announcement?
What is ADIA's Adia Vita stem cell product specification announced in February 2025?
How did ADIA's Winter Park Clinic perform financially in January 2025?
What steps is ADIA taking toward uplisting from OTC Pink in February 2025?
